Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis

Next Previous
Trial Profile

Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tabalumab (Primary) ; Tabalumab (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

  • 23 Nov 2018 I have updated the locations i.e removed Canada.Checked NCT and Eudra records, results are not specifying locations both Eudra & NCT.
  • 29 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 24 Mar 2012 Planned number of patients changed from 245 to 500 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top